Leadership Team

Ulrich Dauer, PhD

Chief Executive Officer, Executive Director

Ulrich Dauer joined the Company as CEO on May 1, 2018. He has had a career spanning more than 20 years in the biopharmaceutical industry in both public and private companies.

As one of the founders, Ulrich Dauer previously worked for 14 years as CEO of 4SC AG, attracting multiple private and, upon the company’s listing at the Prime Standard segment of Deutsche Börse in 2005, public investors. Under his leadership, 4SC closed multiple industry partnerships with international biopharmaceutical companies. In subsequent leadership positions in the biotech industry, he executed in 2014 the €130 M trade sale of Activaero and later took up CEO positions of two privately held biotech companies.

Ulrich Dauer holds a PhD in Chemistry from the Julius-Maximilians University of Würzburg.

Florian Schmid

Chief Financial Officer, Executive Director

Florian Schmid came to Vivoryon as CFO on April 1, 2021. He has twenty years of finance leadership experience in public biopharmaceutical and technology businesses.

Mr. Schmid joins Vivoryon from InflaRx, where he served as Director Finance & Controlling supporting various financing transactions including a US IPO.

Prior to that role, Mr. Schmid spent nearly six years at T‐Systems International GmbH, where he most recently led the Global Deal & Business Support department. Florian Schmid began his career as certified Tax Advisor and Public Accountant at Arthur Andersen and Ernst & Young.

Mr. Schmid received a business degree from the Ludwig‐Maximilian‐University, Munich.

Michael Schaeffer, PhD

Chief Business Officer, Executive Director

Michael Schaeffer has been Chief Business Officer of Vivoryon since October 1, 2018. Michael Schaeffer brings more than 15 years of experience across pharma and biotech in strategic business development, scientific project and alliance management to Vivoryon Therapeutics.

Micheal Schaeffer is a highly experienced serial entrepreneur and was prior to joining our company, – amongst others – Founder, CEO and Managing Director of biotech companies, CRELUX GmbH and SiREEN AG. Following the acquisition of CRELUX by WuXiAppTec in 2016, Dr. Schaeffer was responsible for integrating CRELUX into the world-leading Shanghai based CRO with over 25,000 employees globally.

Michael Schaeffer received his PhD in Molecular Biology from Ludwig-Maximilians-Universität in Munich, Germany and is an exceptionally skilled Operations- and Innovation Manager.

Frank Weber, MD

Chief Medical Officer

Frank Weber, MD, has served as the Company’s Chief Medical Officer since 2012.

Frank brings 30 years of experience in the pharmaceutical and life science industry. Prior to his position at Vivoryon, he served as Chief Medical Officer at Merck KGaA in Germany and Switzerland, before joining Californian InterMune (now Genentech/Roche) as Global Clinical Advisor. He started his career with various management positions in medical affairs and clinical development at American Cyanamid (Lederle), in 1991, USA and at Synthelabo (now Sanofi) ,1993 France.

Frank received his MD in Cancer Immunology at the Medical University Cologne, Germany.

Non-Executive Board Members

Erich Platzer, MD, PhD, is a business angel and board member of Swiss angel organizations StartAngels­Network and BioBAC, focusing on life Sciences and hightech investments.  He is a board member and healthcare partner at Swiss venture capital firm MTIP in Basel, which focuses on MedTech and e-health investments. Prior, he was investment advisor and industry partner at HBM Partners AG, a venture capital company, which he co-founded in 2001. He currently serves as chairman of privately held life sciences companies, AOT, LMD, and credentis AG, as well as on the board of Peripal and public biotech company Aptose Biosciences (NASDAQ, TSE). Until 1999, Erich Platzer worked in various functions in product development and marketing at F. Hoffmann – La Roche, Basel, most recently as Business Director Oncology (worldwide). Prior to that, he actively worked in academic medicine and research and had a key role in the team that purified natural human G-CSF, which lead to the development of Neupogen® and Neulasta®. Erich Platzer holds an MD from the Medical School of the University of Erlangen where he also earned his MD, Ph.D (Habilitation).





Dinnies Johannes von der Osten, PhD, is CEO/Partner at GoodVent Beteiligungsmanagement GmbH & Co KG. Between 1998 and 2007 he was sole managing director of IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH. Before that he worked as managing director of VWM Waste und Beteiligungsgesellschaft mbH (1994-1997) after having been BDO of TechnoCommerz GmbH, a Treuhandanstalt owned company (1993-1994). Dinnies von der Osten holds a PhD in economics from Free University of Berlin, a diploma in economics from Ludwig-Maximilians-University, Munich and a Bachelor of Business and Engineering from TU Karlsruhe.




Charlotte Lohmann has been Senior Vice President since January 2018 and General Counsel since May 2012 at MorphoSys AG in Planegg/Munich. Prior to this, she spent eleven years at Wilex AG in Munich, her last position as Senior Vice President Legal Affairs & Human Resources. Prior to her position at Wilex, she practiced as a lawyer at the law firm KPMG Treuhand & Goerdeler GmbH in Munich. She started her career in the tax and law department of the auditing company KPMG Deutsche Treuhand-Gesellschaft AG in the Munich office. Ms. Lohmann received her degree in law from the University of Munich and is a licensed attorney.





Jörg Neermann, PhD, joined the Company´s board in 2012. He is the CEO of privately held German Biotech company Curexsys. Before taking on the CEO position he was for more than fourteen years a Partner at the life science-focused investment firm of LSP and has served on numerous life sciences company boards (both private and public). In addition to the Vivoryon board, he currently is a member of the board of Immunic Inc. (Nasdaq: IMUX). Prior to joining LSP, Jörg was Managing Director at DVC Deutsche Venture Capital (a venture capital subsidiary of Deutsche Bank), where he built and ran its healthcare investment franchise. Prior to DVC, he started his venture capital career with Atlas Venture as an associate and investment manager. During his career, he led and completed more than 80 financing transactions and was intimately involved in more than 15 M&A transactions and IPOs with a total transaction volume exceeding a billion euros. Jörg studied biotechnology at the Technical University in Braunschweig, Germany, and the Massachusetts Institute of Technology in Cambridge, Mass., and holds a master’s degree and a PhD in Biotechnology from the Technical University in Braunschweig, Germany. He also studied economics at the Technical University in Braunschweig, Germany, and at Harvard Business School. Jörg brings to Vivoryon a strong scientific background and hands-on finance and investment expertise.